SRR8518209
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.570
- MYC_TARGETS_V2+0.400
- MYC_TARGETS_V1+0.370
- BILE_ACID_METABOLISM+0.250
- FATTY_ACID_METABOLISM+0.220
- ADIPOGENESIS+0.200
- PEROXISOME+0.150
- PANCREAS_BETA_CELLS+0.060
- SPERMATOGENESIS+0.060
- KRAS_SIGNALING_DN+0.050
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.620
- TNFA_SIGNALING_VIA_NFKB-0.520
- ANGIOGENESIS-0.510
- INTERFERON_GAMMA_RESPONSE-0.510
- IL6_JAK_STAT3_SIGNALING-0.490
- INFLAMMATORY_RESPONSE-0.480
- HEDGEHOG_SIGNALING-0.470
- INTERFERON_ALPHA_RESPONSE-0.470
- TGF_BETA_SIGNALING-0.470
- HYPOXIA-0.410
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-55-6972-01A-11R-1949-07 | — | cohortA2 | 0.929 |
| 2 | R16 | — | — | 0.919 |
| 3 | SRR1313092 | — | B | 0.917 |
| 4 | TCGA-LL-A6FP-01A-11R-A31O-07 | — | B | 0.911 |
| 5 | SRR10900578 | — | — | 0.904 |
| 6 | s0095168 | — | — | 0.895 |
| 7 | TCGA-CN-A63U-01A-11R-A30B-07 | — | — | 0.893 |
| 8 | 20140146.LumB | — | B | 0.893 |
| 9 | SRR23303740 | — | — | 0.892 |
| 10 | cf2834ac-00ed-4372-be25-042f38241196 | — | — | 0.887 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.570 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.400 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.370 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.250 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.220 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.200 | Inavolisib | — uncovered |
| PEROXISOME | 0.150 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.060 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.060 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.050 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.030 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.010 | Remibrutinib | — uncovered |